Ophthotech Corporation Культура компании

Ms. Barbara A. Wood, Esq., has been Senior Vice President, General Counsel and Secretary of Ophthotech Corporation since November 2013. Ms. Wood served as Senior Vice President of OSI Pharmaceuticals Inc., since October 2007 and served as its Secretary since January 2004. Ms. Wood served as General Counsel of OSI Pharmaceuticals Inc., since April 2001. She served as Vice President of OSI Pharmaceuticals since April 2001 until October 2007. Ms. Wood practiced law at Wood Legal from January 2011 to November 2013. From April 2001 to December 2010, Ms. Wood served in varying roles at OSI Pharmaceuticals, Inc. Prior to OSI, she was a Partner at Squadron, Ellenoff, Plesent and Sheinfeld, LLP, a New York law firm which is now part of Hogan & Hartson, LLP, where she commenced her legal career in September 1987 and focused on mergers and acquisitions, biotechnology, licensing, securities and venture capital matters. She serves as a Director of New York Biotechnology Association Inc. Ms. Wood holds a Bachelor of Arts degree in Classics and Economics from Connecticut College and a J.D. from Columbia Law School where she was a Harlan Fiske Stone Scholar.

Dr. Samir C. Patel, M.D., Co-founded Ophthotech Corporation in January 2007 and served as its President since January 2007 until January 13, 2017. Dr. Patel served as the Chief Executive Officer of Ophthotech Corporation since January 2007 until April 2013. Dr. Patel Co-founded Eyegate Pharmaceuticals, Inc. and served as its Clinical Consultant. Dr. Patel served as the Chief of Clinical and Commercial Strategy and Chief Medical Officer of EyeTech Pharmaceuticals Inc. since January 2005. Previously, Dr. Patel served as a Consultant to EyeTech Pharmaceuticals Inc. from October 2001 to December 2004. Dr. Patel Co-founded Eyetech Pharmaceuticals, Inc. Dr. Patel served as the Residency Program Director at the University of Chicago from 1992 to July 2000. He serves as the Vice Chairman at Ophthotech Corporation. He served as a Director of Ophthotech Corporation since January 2007 until January 13, 2017. Dr. Patel served as an Independent Director of Eyetech Pharmaceuticals Inc. since February 2000. He served as a Director of Eyegate Pharmaceuticals, Inc. He served as a Director of Mimetogen Pharmaceuticals Inc. since March 1, 2007. From 1992 to June 2003, Dr. Patel served as a Director of the Retina Service at the University of Chicago and also served as its Associate Professor. Dr. Patel was the first surgeon to perform a retinal transplant in humans in the United States. Dr. Patel holds an M.D. from the University of Massachusetts Medical School and was an Ophthalmology Resident at the University of Chicago. Dr. Patel completed his fellowship training in retinal surgery at the Massachusetts Eye and Ear Infirmary, a teaching affiliate of Harvard Medical School.

Mr. David F. Carroll, also known as Dave, M.B.A. has been Chief Financial Officer and Treasurer at Ophthotech Corporation since April 24, 2017 and served as its Senior Vice President of Finance. Mr. Carroll joined Ophthotech in June 2016 and served as Senior Vice President of Finance from June 2016 to April 2017. Mr. Carroll served in several senior financial leadership roles at The Medicines Company from May 2008 to June 2016, including Vice President and Controller from October 2008 to December 2015 and Senior Vice President, Chief Accounting Officer from January 2016 to June 2016. In his career, Mr. Carroll served in various financial management positions of increasing responsibility for Genentech, Inc., a member of the Roche Group, Novartis AG and Bristol-Myers Squibb Company. Mr. Carroll is a certified public accountant and received a B.A. in Economics from Ursinus College and an M.B.A. from Rutgers University.

Mr. Keith Westby, M.B.A. has been the Chief Operating Officer and Senior Vice President of Ophthotech Corporation since January 30, 2017. Mr. Westby served as Senior Vice President of Development Operations at Ophthotech Corporation since October 2014 until January 2017. Mr. Westby served as Vice President of Project Management at Ophthotech Corporation and also served as its Senior Director of Project Management. Mr. Westby has more than 10 years of experience in project and strategic alliance management and manufacturing operations in Biotech companies. Mr. Westby most recently served at Pharmasset, Inc., as Director, Project and Alliance Management, accountable for developing and implementing strategy across manufacturing, research and development, preclinical, clinical, regulatory and finance for both internal and partnered projects. Prior to that, Mr. Westby served in positions of increasing responsibility at Eyetech Pharmaceuticals from January 2002 to December 2005, most recently as Director, Alliance & Project Management, leading multifunctional project teams in the NDA filing and marketing approval of Macugen?? for Age-Related Macular Degeneration. Previously, Mr. Westby served at Tunnell Consulting from 1997 to 2002, where he served as a Senior Consultant in Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a B.S. in Applied Physics from the State University of New York, College at Geneseo, an M.S in Engineering Management from Drexel University and an MBA from Columbia Business School.

Ms. Evelyn Harrison, M.B.A., has been the Chief Clinical Operations Officer Ophthotech Corporation since January 11th 2016. Ms. Harrison served as the Chief Operating Officer of Ophthotech Corporation since August 2007 until January 11th 2016. Ms. Harrison has more than 19 years of management and clinical research experience. Her professional career began in clinical research at a major New York City teaching hospital. She then moved to Hoffmann LaRoche, where she served as Director of Clinical Operations responsible for the development and implementation of strategic programs for Roche's Oncology franchise. From 2000 to 2006, Ms. Harrison was with Eyetech Pharmaceuticals, where she held the management positions of Vice-President and Senior Vice-President of Clinical Research and Development and played a key role in the development and approval of Macugen?? for Age-Related Macular Degeneration. Ms. Harrison continued to play a major role in the transition when Eyetech merged with OSI Pharmaceuticals to become OSI-Eyetech. She has worked on all phases of global clinical trials and has extensive experience in multiple therapeutic areas such as bone-marrow transplantation, organ transplantation, oncology, and virology. Her contributions led to the approval of new drugs such as Zenapax?? and Xeloda?? in the U.S. and Europe. Ms. Harrison holds a B.A. degree in Biology from Hofstra University and the M.B.A. from Manhattan College.

Dr. Kourous A. Rezaei serves as the Senior Vice President and Chief Medical Officer of Ophthotech Corporation. He is a Board certified Ophthalmologist who specializes in the medical and surgical treatment of vitreoretinal diseases, and has been recognized with multiple awards in ophthalmology, including the Beem Fisher Award from the Chicago Ophthalmological Society and the American Academy of Ophthalmology Achievement Award. He had served on the Editorial Board of the Journal of Investigative Ophthalmology & Visual Science (IOVS) and currently is a voting Member on the Board of Directors of the American Society of Retina Specialists (ASRS). He is an Associate Professor of Ophthalmology and the Director of the Vitreoretinal Fellowship Program at Rush University Medical Center and is a Senior Partner at Illinois Retina Associates in Chicago. Previously, he was the Director of Vitreoretinal Service at the University of Chicago. Dr. Rezaei also founded 'ChannelR', a digital media education program for retina specialists. He received his medical degree from the University of Cologne in Germany. He served as Chief Resident while completing his residency at the University of Chicago. Dr. Rezaei completed his vitreoretinal surgery fellowship at the Kresge Eye Institute in Detroit.